The Centrifuge Sessions: Driving Innovation and Investment in Cancer Research

NORTHAMPTON, MA / ACCESS Newswire / April 3, 2025 / We're focused on driving innovation in virology, oncology and immunology - and that includes investing in world-class science to change the way cancer is treated. In the latest episode of The Centrifuge Sessions, hear from Samuel Haile, Ph.D., Director of Cell Biology at Kite Pharma, on how we're working to deliver cell therapies that offer new hope for patients.

Originally published by Gilead Sciences

About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: [email protected]

SOURCE: Gilead Sciences

You May Also Be Interested In

• Abu Dhabi's G42 Weighs US Ownership To Safeguard AI Chip Access - Bloomberg
• Increasing unusual call volume: GPRO DPRO BMEA RARE BBD WRBY CHPT GTM KHC RSI
• Active options: AMZN ORCL PLTR HOOD SOFI META TSLA AVGO MSFT PATH B